mpo

MPO (5-(4'-Methoxyphenyl)-oxazole) is an inhibitor of the hatch and growth of Caenorhabditis elegans.

MPO-IN-28 is a novel potent, irreversible Myeloperoxidase (MPO) inhibitor with IC50 of 44 nM.

5-Aminosalicylic Acid (5-ASA) is a specific PPARγ agonist and also inhibits P21-activated kinase 1(PAK1) and NF-Κb. 5-Aminosalicylic Acid has anti-cancer and anti-inflammatory activities. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

AZD8309 is a potent, orally available antagonist of the chemokine receptor CXCR2 that regulates neutrophil transport, significantly reduces MPO in the pancreas and lung, and decreases trypsin and elastase activity in the pancreas.AZD8309 can be used to study a range of inflammatory diseases.

Cefdinir (FK-482) is a third-generation, semi-synthetic cephalosporin antibiotic effective against common bacterial infections of the ear, sinus, throat, and skin.

Nabumetone (BRL14777)(BRL14777) is a non-steroidal anti-inflammatory drug and its active metabolite 6MNA inhibits the enzymes cyclo-oxygenase I and II.

Melatonin (Melatonine) is a natural hormone secreted by the pineal gland that activates melatonin receptors. Melatonin is a hormone that regulates the biological clock and also has antioxidant and anti-inflammatory activities.

4-Aminosalicylic acid (para-aminosalicylic acid) is an analog of para-aminobenzoic acid (PABA) with antitubercular activity.

AZD5904 is a potent and irreversible human Myeloperoxidase (MPO) inhibitor(IC50 of 140 nM and has similar potency in mouse and rat).

PF-1355 (PF 06281355) is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases.

N-Acetyl lysyltyrosylcysteine amide is a non-toxic, potent, reversible, and specific myeloperoxidase (MPO) tripeptide inhibitor that effectively inhibits MPO production in vivo, attenuates neuronal damage, preserves brain tissue and neurological function post-stroke, and inhibits MPO-dependent hypochlorite (HOCl) production, protein nitration, and LDL oxidation. It is also used in the study of bronchial dysplasia.

Mitiperstat (AZD-4831) is an irreversible, highly selective, oral myeloperoxidase (MPO) inhibitor. Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC₅₀ values of 1.5 nM and 0.69 μM, respectively. Mitiperstat exhibits weak inhibition of CYP3A4 with an IC₅₀ of 6 μM. Mitiperstat is suitable for research into diseases such as chronic obstructive pulmonary disease, heart failure with preserved ejection fraction, and non-alcoholic steatohepatitis.

Myeloperoxidase, human white blood cells (MPO), is a peroxidase enzyme. It modulates oxidative stress by promoting the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS), influencing the polarization of microglia and neutrophils and regulating inflammation-related signaling pathways. Myeloperoxidase, human white blood cells also exhibits antibacterial activity.

MPO-IN-1 is an orally active myeloperoxidase (MPO) inhibitor, inhibiting MPO and thyroid peroxidase (TPO). It is useful in inflammation research.

MPO-IN-6 (compound ADC) is an electrophilic agent with excellent antioxidant and anti-inflammatory properties. It acts as an inhibitor of myeloperoxidase (MPO), dipeptidyl peptidase-4 (DPP-4), and α-glucosidase (α-GD), with IC50 values of 10 μM, 31.02 μM, and 46.05 μM, respectively. MPO-IN-6 may serve as a potential cardiovascular protective agent.

MPO-IN-7 (compound MDC) is a myeloperoxidase inhibitor with IC50 values of 41 μM for α-glucosidase, 25 μM for dipeptidyl peptidase-4, and 4.5 μM for myeloperoxidase. MPO-IN-7 exhibits antioxidant and anti-inflammatory activities in vitro.

MPO-IN-9 is a specific myeloperoxidase (MPO) inhibitor with an IC50 value of 3.9 nM. It suppresses MPO-mediated ROS production and safeguards NO-dependent vascular functions by obstructing the chlorination and peroxidase cycles of MPO. MPO-IN-9 has potential applications in researching diseases such as chronic kidney disease and non-alcoholic steatohepatitis.

MPO-IN-3, a powerful inhibitor of myeloperoxidase (MPO), is described as such in example 191 of WO2013068875A1. MPO, a heme-containing enzyme, is classified under the peroxidase superfamily.

MPO-IN-4 (compound 12) is a potent and selective myeloperoxidase (MPO) inhibitor with an IC50 of 25 nM and also demonstrates inhibition of thyroid peroxidase (TPO) with an IC50 of 2.2 μM. MPO-IN-4 has no effect on methyl guanine methyl transferase (MGMT) [1].

MPO-IN-5 is a potent, irreversible inhibitor of MPO (myeloperoxidase). MPO-IN-5 inhibits MPO peroxidation (IC50: 0.22 μM) and hERG binding (IC50: 2.8 μM). 23000 M 1s 1.

The Anti-Mouse myeloperoxidase/MPO Antibody (6D1) is a mouse-derived antibody of the IgG2bkappa type, targeting MPO. The isotype control for this antibody is the Mouse IgG2bkappa, Isotype Control.

Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is an IgG2c, κ inhibitor antibody from a murine source that targets mouse myeloperoxidase/MPO.

MPO-IN-8, an orally active myeloperoxidase (MPO) inhibitor, effectively inhibits the production of hypochlorous acid in neutrophils and the release of extracellular traps (NETosis). In mice exhibiting gouty arthritis, it reduces swelling, decreases peroxidase activity, and lowers IL-1β levels.

APA-APA-MPO is a PCAF bromodomain/Tat-AcK50 association inhibitor.